A Phase 2 Randomized Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Three Doses of Frevecitinib (KN-002) in Patients with Severe Asthma not Adequately Controlled with Medium to High Dose ICS/LABA Therapy (PANAIRAMA)

Registry ID
2023-509125-41-00
Source registry
CTIS
Status
Authorised
Phase
PHASE2
Study type
INTERVENTIONAL
Sponsor
Kinaset Therapeutics Inc.
Enrollment
70
Last update
2026-08-14

Conditions

Primary outcomes

Change in predose (pre-bronchodilator) FEV1 (L) from baseline to Week 12

Locations

Related clinical trials

View on source registry